Latest Articles

In a recent interview with Technology Networks, Pieter Peeters, Leader of High Dimensional Biology and Discovery Data Sciences Group at Janssen Research & Development, discusses the evolution of artificial intelligence (AI), and how it can be used to discover, develop and test new drugs.

As some of the stricter COVID-19 lockdown restrictions are being eased, some have already experienced a second wave of cases. But might there be a way to predict new epicenters of infection and nip them in the bud before they are able to establish themselves and spread further? Some scientists think so, and the answer lies beneath our feet – wastewater.

A continual pursuit of discovery has brought researchers to, arguably, one of the greatest challenges yet in modern science: the field of metabolomics.

The internet of things (IoT) has been used in hospitals to track people, supplies and equipment so that they can improve workflow, reduce congestion and delays, monitor the condition of equipment and reduce the misplacement of devices. Will it have a similarly game-changing impact in research labs?

In this article, we use COVID-19 and cancer to illustrate the range of screening tools at our fingertips today.

In this article, we explore how automation in the laboratory environment can give the scientist greater control over their instruments to drive up standards and quicken the experimental process.

Biobanks are rich collections of data and biospecimens, specifically developed as resources for research. Cloud-based laboratory information management systems (LIMS) are emerging as a better way to store, analyze and share biospecimens, offering an opportunity for biobanks looking to invest in effective data management solutions to support these interrelated goals.

The #PostItNotePhD challenge asked scientists to summarize their PhD on a single post-it note. Here are a selection of Technology Networks' favorites.

It is an extraordinary time, but it is not an excuse for lowering scientific standards, argue Professor Jonathan Kimmelman, McGill University, and Professor Alex John London, Carnegie Mellon University, in a Policy Forum published in the journal Science . Technology Networks spoke with Kimmelman in a recent interview to gain his insights on research exceptionalism.

Progress in artificial intelligence (AI) offers the exciting possibility of pairing it with cutting-edge lab automation, essentially automating the entire drug development pipeline, from molecular design to synthesis and testing – greatly expediting the process.